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T-cell acute lymphoblastic leukemia (T-ALL) is a biologically heterogeneous disease with respect to phenotype, gene expression
profile and activation of particular intracellular signaling pathways. Despite very significant improvements, current therapeutic
regimens still fail to cure a portion of the patients and frequently implicate the use of aggressive protocols with long-term side
effects. In this review, we focused on how deregulation of critical signaling pathways, in particular Notch, PI3K/Akt, MAPK, Jak/
STAT and TGF-ß, may contribute to T-ALL. Identifying the alterations that affect intracellular pathways that regulate cell cycle
and apoptosis is essential to understanding the biology of this malignancy, to define more effective markers for the correct
stratification of patients into appropriate therapeutic regimens and to identify novel targets for the development of specific, less
detrimental therapies for T-ALL.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most com-
mon childhood malignancy, resulting from the clonal ex-
pansion of lymphoid progenitors that have undergone
malignant transformation at distinct stages of differentia-
tion. Approximately 15% of the cases are of T-cell origin (T-
ALL) (1). Cell-autonomous lesions are certainly at the
origin of T-ALL. However, microenvironmental factors are
also believed to contribute to T-ALL expansion (2,3). Both
cell-intrinsic defects and external stimuli frequently con-
verge on the activation of key ‘pro-oncogenic’ intracellular
pathways. In this review, we focus on the Notch, PI3K/Akt,
MAPK, Jak/STAT and TGF-ß signaling pathways, crucial
for the survival and proliferation of the leukemic blasts
(Figure 1). We present a brief overview of these pathways,
summarize their involvement in T-ALL and discuss their
potential as therapeutic targets.
Notch
Activation of Notch pathway relies on the interaction of
the single pass transmembrane receptor Notch with a
Delta/Serrate ligand of a neighboring cell. This interaction
activates a cascade of proteolytic cleavages that ulti-
mately leads to activation of Notch-target genes and
changes in the transcriptional program. In mammals, four
Notch receptors are described (Notch1-4), which are ho-
mologues of Drosophila notch, and five Notch ligands
(Delta-like-1,3 and 4 and Jagged1-2) that are homologues
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of Drosophila delta/serrate genes, respectively (4).
The Notch receptors are heterodimers that non-co-
valently interact at the cell membrane surface. The extra-
cellular subunit (NEC) interacts with a ligand and the trans-
membrane subunit (NTM), which also contains the cyto-
plasmic effector domains of the receptor. The Notch ligands
are all expressed at the cell surface as monomers or
homodimers (5).
Activation of Notch receptors occurs upon ligand bind-
ing through the EGF-like repeats, present both in ligands
and in the receptors. This interaction induces a conforma-
tional change in the Notch receptor that leads to two
successive proteolytic cleavages, by metalloprotease tu-
mor necrosis factor converting enzyme and by the γ-
secretase complex. Consequently, intracellular Notch do-
main (ICN) is released and translocates into the nucleus.
Nuclear ICN is capable of binding to CSL (CBF1, Suppres-
sor of Hairless, and Lag1) and form a ternary complex with
Mastermind-like proteins (MAML1-3), leading to the tran-
scriptional activation of Notch-target genes. The best char-
acterized Notch-target genes include Notch-signal modu-
lator Deltex1, Hairy/enhancer of split (HES1-5) and Hairy-
related (HRT, HEY) gene family members. These genes
are up-regulated upon Notch signaling and have been
implicated in the modulation of proliferation, differentiation
and survival (4).
Notch involvement in T-ALL was first described in three
patients with t(7;9)(q43;q34.3), which juxtaposes the TCRß
locus to the C-terminal coding region of the Notch1 gene.
This translocation leads to the expression of a truncated,
cytoplasmic form of Notch1 receptor with constitutive ac-
tivity (6). Human truncated Notch1 was shown to be highly
oncogenic, since transduction of mouse bone marrow
cells with retroviruses encoding the corresponding se-
quence of Notch1 leads to the development of T-cell
leukemia with high penetrance in the transplanted animals
(7), and the effect is synergistic with those of other known
oncogenes, including c-Myc and E2A-PBX1 (8,9). Despite
these striking observations, t(7;9)(q43;q34.3) is very rare,
accounting for less than 1% of T-ALL cases (10). However,
the involvement of Notch1 in the pathogenesis of this
disease was strongly supported by the discovery that more
than 50% of T-ALL cases harbored mutations in the Notch1
alleles, resulting in the constitutive activation of the path-
way (10). The mutations were found in two different sites in
the NTM subunit, the HD domain and the PEST sequence.
The HD mutations enhance γ-secretase-dependent pro-
teolytic cleavages in the receptor, whereas the PEST
Figure 1. Schematic representation of the
signaling pathways that appear to contri-
bute to proliferation and survival of T-cell
acute lymphoblastic leukemia (T-ALL)
cells. Several signaling components have
been implicated in the regulation of T-ALL.
The chimeric TEL-Jak2 protein is ex-
pressed in T-ALL due to t(9;12)(p24;p13)
and is capable of phosphorylating STAT1
and STAT5, which could promote T-ALL
proliferation. The Notch pathway was
shown to be constitutively activated in
more than 50% of T-ALL patients. The loss
of Smad3 expression was demonstrated in
some T-ALL cases, and may synergize
with other oncogenic events in the devel-
opment of this malignancy. Constitutive
activation of the PI3K/Akt pathway was
demonstrated in T-ALL cell lines and our
own data indicate that it is highly frequent
in primary leukemia cells. This essentially
results from PTEN inactivation by different
mechanisms. Mutations in MAPK family
members have not been reported in T-
ALL. However, tumor-supportive signals from the microenvironment likely activate Erk1/2 and Erk5. Erk1/2 phosphorylates the T-cell
oncogene Tal1, and Erk5 phosphorylates NF-κB, contributing to the viability and proliferation of leukemic cells. Similarly, extracellular
cues (cytokines/chemokines, growth factors, adhesion molecules, Notch ligands, etc.) leading to the activation of Notch or Jak/STAT
pathways are probably present within the leukemic milieu. Although microenvironmental signals are unlikely to trigger the oncogenic
process, they appear to contribute to the maintenance/proliferation of the malignant clones. ICN = intracellular Notch domain: CSL =
CBF1, Suppressor of Hairless, and Lag1; MAML = Mastermind-like proteins.
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mutations result in premature stop codons and conse-
quent deletion of the PEST domain that increases the half-
life of ICN (11). Similar mutations were found in T-ALL
mouse models (12). In addition, non-mutational Notch1
activation seems to be an early event in the development
of T-ALL in mouse models (13), and recent work identified
c-Myc as a Notch1-target gene highly up-regulated in T-
ALL and critical for Notch1-mediated leukemogenesis (14).
Notch3 receptor has also been implicated in T-cell
leukemogenesis. A transgenic mouse model that expresses
Notch3ICN in thymocytes develops aggressive T-cell leuke-
mias of immature phenotype (15). This phenotype was
shown to be dependent on constitutive preTCR signaling
that induces activation of NF-κB, inhibition of E2A activity
and Tal1 expression, contributing to the survival and prolif-
eration of these tumors (16). However, it is not known how
Notch3 can promote aberrant signaling capable of leuke-
mogenesis, since it is normally expressed throughout T-
cell ontogeny.
In contrast to Notch1 and -3, Notch2 and -4 have not
been associated with T-ALL, and the only Notch ligand
implicated in the disease so far was Dll4. Retroviral-medi-
ated transduction of bone marrow cells with Dll4 induced a
lymphoproliferative disease of CD4+CD8+ double-positive T-
cell precursors. Transplantation of these cells resulted in the
establishment of aggressive leukemia in recipient mice (17).
As mentioned previously, Notch signaling is depend-
ent on a cascade of proteolytic cleavages, one of which is
catalyzed by γ-secretase complex in the S3 cleavage site.
In fact, inhibition of Notch signaling by γ-secretase inhibi-
tors (GSI), already available for treatment of Alzheimer
disease, was shown to prevent growth and induce apopto-
sis of T-ALL cell lines in vitro (10,18). Consequently, GSI
were regarded as very promising therapeutic tools for T-
ALL (19). Nevertheless, the efficiency of these drugs in
patients demands confirmation, since T-ALL cells seem to
be frequently resistant to GSI treatment in vitro, perhaps
due to activation of PI3K/Akt pathway (20).
PI3K/Akt
Phosphatidylinositol-3OH-kinase (PI3K) pathway regu-
lates various cell functions including proliferation and ap-
optosis, through activation of different downstream effec-
tors, of which the most prominent is the Ser/Thr kinase Akt
(also called PKB, Protein Kinase B). At the cell membrane
PI3K has the ability to phosphorylate phosphatidylinositol
4,5-biphosphate (PIP2) at the 3-position of the inositol ring,
generating phosphatidylinositol 3,4,5-triphosphate (PIP3).
PIP3 act as second messengers and serve as membrane
anchors for proteins with a pleckstrin homology (PH) do-
main, such as Akt and PDK1. The colocalization of Akt and
PDK1 at the cell membrane favors Akt phosphorylation
and consequent activation (21). Akt generates anti-apop-
totic and pro-proliferative signals through the inhibitory
phosphorylation of Bad, GSK3, Forkhead (FOXO1) and
caspase-9, through the activating phosphorylation of
mTOR, and through the release of transcriptional factors
such as NF-κB (21,22). The tumor suppressors PTEN and
SHIP dephosphorylate PIP3, acting as negative regulators
of the PI3K/Akt pathway (21).
In T-ALL, the PI3K/Akt pathway is activated by growth
factors present in the leukemia milieu that signal through
cytokine receptors (2,23). Moreover, T-ALL cell lines pres-
ent constitutively phosphorylated forms of Akt independ-
ently of external growth factors (20). In addition, NF-κB, a
downstream target of PI3K/Akt, is constitutively activated
in some primary T-ALL samples (24). Nevertheless, no
activating mutations of PI3K and/or Akt have been de-
scribed in T-ALL. It has been suggested that PI3K/Akt
pathway over-activation results from PTEN protein down-
regulation and/or SHIP mutations (25,26). However, re-
sults from our lab show that non-deletional inactivation of
PTEN is a major contributor to hyperactivation of PI3K/Akt
in primary T-ALL samples (Silva A, Yunes JA, Cardoso BA,
Martins LR, Jotta PY, Abecasis M, Nowill AE, Leslie NR,
Cardoso AA, Barata JT, unpublished data). PTEN muta-
tions resulting in protein truncation have been identified
more frequently in T-ALL cell lines established from re-
lapsed patients (30.4%) than in diagnostic clinical speci-
mens (5.2%), which suggests that PTEN deletion is a late
event in human T-ALL (25). In contrast, recent studies
using mouse models have shown that PTEN deregulation
is important at early stages of leukemogenesis. In these
models, PTEN expression was shown to be essential to
maintain the hematopoietic stem cell pool and to prevent
leukemia development (27,28).
As mentioned previously, PI3K activates several down-
stream signal transduction pathways including mTOR.
Rapamycin, a specific inhibitor of mTOR, stimulates apop-
tosis of pediatric T-ALL cells (29,30), reverses the chemore-
sistance of Notch1-overexpressing leukemic cells (31)
and restores the normal function of hematopoietic stem
cells from PTEN-deleted mice (27).
Several therapeutic strategies targeting PI3K pathway
are now in development. In a number of studies the in vitro
use of specific PI3K pharmacologic inhibitors, such as
LY294002 and wortmannin, and natural compounds with
PI3K inhibitory capacities, such as resveratrol, increased
apoptosis and arrested the cell cycle in T-ALL cells (32,33).
PI3K inhibition is also important to abolish chemoresis-
tance to drugs used in current therapeutic regimens or that
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are being tested in clinical trials (20).
MAPKs
Mitogen-activated protein kinases (MAPKs) are a fam-
ily of evolutionary conserved Pro-directed Ser-Thr kinases,
which play a central role in transducing extracellular cues
into a variety of intracellular responses including the modu-
lation of cell proliferation, differentiation and apoptosis
(34). The activity of MAPKs depends on the phosphoryla-
tion state of the Thr and Tyr residues in a TXY motif within
their kinase domain. This canonical motif is also used to
classify MAPKs into three sub-families. X corresponds to
Glu in the extracellular signal-regulated kinases (Erks), to
Pro in the c-Jun N-terminal kinases (JNK 1, 2, and 3) and
to Gly in the p38 (α, ß, γ, and δ isoforms) (34). The Erk sub-
family comprises not only the widely studied Erk1 and
Erk2, but also the more recently identified Erk5, containing
an extended C-terminal domain that confers to it additional
properties (35). External stimuli, consisting mainly, but not
exclusively, of growth factors in the case of Erks and stress
stimuli in the case of JNK and p38 (36), activate membrane
receptors, which then turn on a cascade of activating
phosphorylations. These proceed from an MAPKKK (MAPK
kinase kinase) to an MAPKK (MAPK kinase) and finally to
the MAPK. Once activated, MAPKs phosphorylate a num-
ber of cytosolic and nuclear substrates, leading to the
diverse biological effects mentioned above (37).
Despite extensive evidence implicating activation of Erk
pathway in cancer progression, the involvement of MAPKs
in T-ALL is not clearly established. Neither JNK nor p38 have
been shown to be altered in T-ALL. In contrast, there is
evidence that Erks may contribute to T-ALL biology. T-cell
Acute Leukemia 1 (Tal1) is a basic helix-loop-helix transcrip-
tion factor involved in early hematopoiesis and normally
down-regulated upon T-cell lineage commitment. Alterations
in the tal1 gene, leading to its overexpression, are the most
common genetic lesion in T-ALL (38). Tal1 oncogenic ef-
fects are thought to be mediated, at least in part, by
heterodimerization and consequent inactivation of E2A/HEB
tumor suppressor proteins (39). Aberrant activation of the
Tal1 protein by phosphorylation via Erk1 has also been
described in the human T-ALL cell line Jurkat (40). This
modification has been suggested to positively regulate Tal1
transactivation potency (41) and may therefore link Erks to
T-ALL leukemogenesis. However, there are no reported
Erk-activating mutations in T-ALL as far as we know. Not-
withstanding, activation of Erk1/2 has been observed in T-
ALL cells on stimulation with IL-7. In contrast, normal T-cells
do not appear to activate Erk1/2 in response to IL-7 (22).
Despite this clear difference, the exact biological role of
activation of Erk pathway remains to be elucidated, since it
does not apparently have any major consequences on
proliferation or viability of T-ALL cells (2).
In Jurkat T-ALL cells, Erk5 was also recently demon-
strated to drive the phosphorylation, directly or via Rsk1, of
the p65/RelA subunit of NF-κB. As a consequence, p65/
RelA is maintained in the nucleus, where it acts as a
transcription factor for survival genes. This decreases
apoptosis and has been proposed to be essential for the
survival of leukemic T-cells (42).
Since both Erk1/2 and Erk5 have been reported to
contribute to the survival of leukemic T-cells, they are logical
candidates for therapy. Their inactivation with the use of
pharmacologic inhibitors of upstream molecules, such as
PD98059 and U0123 for MEK (MAPKK) and BAY-43-9006/
Sorafenib for Raf (MKKK), as well as their down-regulation
through antisense approaches, are currently being studied
for cancer treatment, although not specifically in the context
of T-ALL (43). Therapies involving the activation of the
stress-induced MAPKs have also been described. The glu-
cocorticoid and common therapeutic agent dexamethasone
has been shown to induce apoptosis of the human T-ALL
cell line CCRF-CEM by activating p38, which in turn induces
transcription of bim, a pro-apoptotic Bcl-2 family member
(44). Further, arachidonic acid has been shown to have an
anti-proliferative effect in Jurkat cells mediated at least in
part by the activation of JNK (45).
Jak/STAT
The evolutionarily conserved Janus kinase-signal trans-
ducer and activator of transcription (Jak/STAT) pathway
plays an important role in biological processes such as
apoptosis, differentiation, proliferation and cellular immune
responses, mediated by growth-factors and cytokines (46).
Binding of cytokines results in cell surface receptor oligo-
merization and activation of the Jak family of tyrosine
kinases (47). Activated Jaks phosphorylate the cytoplas-
mic domain of the receptor, thereby creating docking sites
for STATs, which are phosphorylated by Jaks and conse-
quently dimerize and migrate to the nucleus where they
regulate gene transcription (47). Although rarely mutated,
STATs are frequently overexpressed and hyperactivated
by alterations in upstream signaling pathways, participat-
ing in oncogenesis through up-regulation of genes encod-
ing apoptosis inhibitors (Mcl-1, Bcl-x) and cell cycle regu-
lators (cyclins D1/D2, c-Myc) (48).
In pediatric T-ALL, the genetic juxtaposition between
JAK2 and the ETS-family member TEL results from
t(9;12)(p24;p13) chromosomal translocation, and originates
a constitutively active TEL-Jak2 chimeric protein (49).
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Strikingly, TEL-Jak2 transgenic mice develop fatal leuke-
mia, displaying a selective expansion of CD8-positive T-
cells in blood, lymph nodes, thymus, spleen, and bone
marrow, and also invasion of non-hematopoietic organs by
leukemic T-cells (49). These observations support the no-
tion that TEL-JAK2 is an oncogene in vivo. Interestingly,
the expression of a tyrosine-phosphorylated TEL-Jak2 pro-
tein correlates with activation of STAT1 and STAT5 in
leukemic tissues (49). Moreover, TEL-Jak2, in addition to
activating STAT5, appears to associate with Shc and Grb2
and induce activation of Erk2 (50).
Activation of STAT5 in T-ALL may arise from other
mechanisms. For example, the cryptic t(9;14)(q34;q32),
associated with deletion of p16 and expression of HOX11,
was recently reported in a T-ALL patient, and results in the
aberrant expression of a constitutively phosphorylated
tyrosine kinase fusion protein between Echinoderm micro-
tubule-associated protein-like 1 (EML1) and Abelson 1
(ABL1) (51). When overexpressed in IL-3-dependent Ba/
F3 cells, EML1-ABL1 allows for growth factor-independent
expansion of these cells through activation of survival and
proliferation pathways, including Erk1/2, Lyn kinase and
STAT5. These data further suggest the involvement of
ABL1 fusions in the pathogenesis of some T-ALL cases,
which may benefit from treatment with glivec/imatinib (51).
Activation of other STATs has been observed in human
leukemias. In addition to STAT5, STAT1 and STAT3 ap-
pear to be constitutively activated in some ALL patient
specimens (52). Moreover, methylation of SHP-1, a pro-
tein tyrosine phosphatase that acts as a negative regulator
of the Jak/STAT pathway, was found in ALL primary cells
and in the T-ALL cell line Jurkat, which may account for the
constitutive activation of Jak and STAT3 (53). However,
only STAT1 and STAT5 were reported to be constitutively
activated in primary T-ALL (54). In addition to cell-autono-
mous lesions, activation of the Jak/STAT pathway may
occur in response to cytokines and growth factors present
in the leukemic microenvironment, thereby contributing to
T-ALL disease progression. For instance, the ‘pro-leuke-
mic’ cytokine IL-7 (22), was shown to induce Jak1, Jak3
and STAT5 activation in T-ALL cells (55). Altogether, and
despite the evidence for Jak and STAT activation in some
T-ALL patients and cell lines, Jak/STAT signaling has not
been extensively demonstrated in patient specimens. Thus,
the therapeutic potential of targeting this pathway remains
largely speculative at this stage.
TGF-ß
Transforming growth factor-beta (TGF-ß) plays an im-
portant role in cellular homeostasis by regulating cell growth
inhibition, cellular senescence, differentiation and apopto-
sis (56). Smad2 and Smad3, the principal cytoplasmic
intermediates involved in the transduction of signals from
TGF-ß receptors, are activated when TGF-ß binds to its
cell-surface receptor and translocate from the cytoplasm
to the nucleus, where they regulate gene transcription
(57). While TGF-ß is a potent negative regulator of he-
matopoiesis (58), the importance of down-regulated TGF-
ß signaling in leukemogenesis has started to emerge.
Wolfraim and colleagues (59) described the loss of
Smad3 in T-ALL pediatric patient cells, although no muta-
tions in the Smad3 gene (MADH3) were found. Moreover, T-
ALL cells display normal Smad3 mRNA levels, suggesting
that Smad3 deletion occurs at the posttranslational level.
Additionally, the authors showed that deletion of Smad3 can
synergize with oncogenic events, such as loss of p27kip1, in
promoting T-cell leukemogenesis in mice. These data sug-
gest that Smad3 may act as T-cell tumor suppressor and that
defective TGF-ß signaling, either as a result of cell-intrinsic
lesions or an altered microenvironmental context, may con-
tribute to T-cell leukemogenesis. Strategies aimed at restor-
ing Smad3 expression in T-ALL may prove beneficial, but
are technically and clinically extremely challenging.
Concluding remarks
Alterations in signaling pathways play distinct roles in the
etiology, maintenance and progression of T-ALL (Figure 1).
Notch pathway is clearly deregulated in this type of leuke-
mia. However, it is likely that Notch-signaling inhibitors (GSI
compounds) will not be effective as single agents, and
strategies involving their combination with drugs that inhibit
other targets should be required. For example, chemoresis-
tance to Notch inhibitors may be abolished by targeting the
PI3K/Akt pathway (20). Additionally, our own data suggest
that inclusion of inhibitors of PI3K pathway into current
pediatric T-ALL therapeutic protocols may be of particular
relevance. Despite the evidence for mis-regulation of MEK/
Erk, JAK/STAT and TGF-ß signaling pathways, involved in
viability and proliferation, their exact relevance in primary T-
ALL remains to be fully unraveled. Nonetheless, it is very
plausible that the oncogenic signatures of some T-ALL
cases embrace activation of these key pathways, and that
those cases may benefit from tailor-made therapies involv-
ing the use of signaling-specific antagonists.
Overall, we suggest that the analysis of the intracellular
signaling profile of T-ALL patients could not only serve to
reveal novel molecular targets for treatment of this dis-
ease, but also to identify critical biomarkers for accurate
and clinically relevant diagnosis and prognosis of T-ALL
patient subsets.
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